73 related articles for article (PubMed ID: 17391324)
1. Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans?
Kudzi W; Dodoo AN; Mills JJ
BMC Med Genet; 2010 Jul; 11():111. PubMed ID: 20630055
[TBL] [Abstract][Full Text] [Related]
2. MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males.
Zhang Y; Jiang XH; Hu YQ; Li ZR; Su L; Wang ZG; Ma G
Br J Clin Pharmacol; 2008 Aug; 66(2):247-54. PubMed ID: 18460034
[TBL] [Abstract][Full Text] [Related]
3. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response.
Fonseca F; de la Torre R; Díaz L; Pastor A; Cuyàs E; Pizarro N; Khymenets O; Farré M; Torrens M
PLoS One; 2011 May; 6(5):e19527. PubMed ID: 21589866
[TBL] [Abstract][Full Text] [Related]
4. Effects of CYP3A5*3 genetic polymorphisms on the pharmacokinetics of perampanel in Chinese pediatric patients with epilepsy.
Zhao T; Feng JR; Zhang HL; Yu J; Feng J; Sun KF; Yu LH; Sun Y; Li HJ
Pharmacogenet Genomics; 2024 May; ():. PubMed ID: 38728170
[TBL] [Abstract][Full Text] [Related]
5. Combined Analysis of HLA Class II Eplet Mismatch and Tacrolimus Levels for the Prediction of De Novo Donor Specific Antibody Development in Kidney Transplant Recipients.
Lee H; Min JW; Kang H; Lee H; Eum SH; Park Y; Yang CW; Chung BH; Oh EJ
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806362
[TBL] [Abstract][Full Text] [Related]
6. Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis.
Yan M; Fan X; Si H; Wang X; Wang Z; Wang Z; Lv X; Yin H; Jia Y; Jiang L; Xia Y; Liu Y
Cancer Chemother Pharmacol; 2022 Feb; 89(2):173-181. PubMed ID: 34988655
[TBL] [Abstract][Full Text] [Related]
7. Effect of MDR1 gene polymorphisms on mortality in paraquat intoxicated patients.
Kim HJ; Kim HK; Kwon JT; Lee SH; El Park S; Gil HW; Song HY; Hong SY
Sci Rep; 2016 Aug; 6():31765. PubMed ID: 27545861
[TBL] [Abstract][Full Text] [Related]
8. Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.
Wolking S; Schaeffeler E; Lerche H; Schwab M; Nies AT
Clin Pharmacokinet; 2015 Jul; 54(7):709-35. PubMed ID: 25860377
[TBL] [Abstract][Full Text] [Related]
9. Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients.
Sharaki O; Zeid M; Moez P; Zakaria NH; Nassar E
Mol Biol Rep; 2015 Jan; 42(1):105-17. PubMed ID: 25240575
[TBL] [Abstract][Full Text] [Related]
10. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies.
Rojas L; Neumann I; Herrero MJ; Bosó V; Reig J; Poveda JL; Megías J; Bea S; Aliño SF
Pharmacogenomics J; 2015 Feb; 15(1):38-48. PubMed ID: 25201288
[TBL] [Abstract][Full Text] [Related]
11. MDR1 gene polymorphisms are associated with glucocorticoid-induced avascular necrosis of the femoral head in a Chinese population.
Xue Y; Zhao ZQ; Hong D; Zhang HJ; Chen HX; Fan SW
Genet Test Mol Biomarkers; 2014 Mar; 18(3):196-201. PubMed ID: 24387690
[TBL] [Abstract][Full Text] [Related]
12. A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation.
Sy SK; Heuberger J; Shilbayeh S; Conrado DJ; Derendorf H
AAPS J; 2013 Oct; 15(4):1189-99. PubMed ID: 23990505
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study.
Li L; Li CJ; Zheng L; Zhang YJ; Jiang HX; Si-Tu B; Li ZH
Eur J Clin Pharmacol; 2011 Aug; 67(8):787-95. PubMed ID: 21331500
[TBL] [Abstract][Full Text] [Related]
14. The investigation of allele and genotype frequencies of CYP3A5 (1/3) and P2Y12 (T744C) in Iran.
Azarpira N; Namazi S; Khalili A; Tabesh M
Mol Biol Rep; 2011 Nov; 38(8):4873-7. PubMed ID: 21153923
[TBL] [Abstract][Full Text] [Related]
15. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
[TBL] [Abstract][Full Text] [Related]
16. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function.
Fung KL; Gottesman MM
Biochim Biophys Acta; 2009 May; 1794(5):860-71. PubMed ID: 19285158
[TBL] [Abstract][Full Text] [Related]
17. Impact of CYP3A5 genetic polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects.
Suzuki Y; Homma M; Doki K; Itagaki F; Kohda Y
Br J Clin Pharmacol; 2008 Jul; 66(1):154-5. PubMed ID: 18341670
[No Abstract] [Full Text] [Related]
18. Tacrolimus once-daily formulation: in the prophylaxis of transplant rejection in renal or liver allograft recipients.
Cross SA; Perry CM
Drugs; 2007; 67(13):1931-43. PubMed ID: 17722962
[TBL] [Abstract][Full Text] [Related]
19. Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects.
Choi JH; Lee YJ; Jang SB; Lee JE; Kim KH; Park K
Br J Clin Pharmacol; 2007 Aug; 64(2):185-91. PubMed ID: 17391324
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
